COVID-19 Nanobody
COVID-19
Pre-clinicalActive
Key Facts
About VicuTec Biologicals
VicuTec Biologicals is a private, preclinical-stage biotech based in Munich and Dortmund, Germany, developing a robust nanobody platform. The company's technology, originating from the Max Planck Institute and University Medical Center Göttingen, enables rapid, cost-effective production of highly potent nanobodies in microbial systems. Its initial pipeline targets major infectious diseases including COVID-19, MRSA, Tuberculosis, and Malaria, with backing from the EU Malaria Fund and strategic academic partnerships.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |